Neuro Event Labs

Neuro Event Labs: problem, solution and market

Management

Neuro Event Labs is led by a team with long experience in MedTech, software and epilepsy care, supported by an active board of industry and investor representatives. The team combines commercial, technical and clinical experience, which is important for scaling a regulated MedTech solution in Europe and the US.

Board of Directors

Company structure

Distribution of company shares

The shareholder base of Neuro Event Labs consists mainly of specialist life science venture funds, the EU’s EIC Fund and an employee option pool for founders and key team members. Hadean Ventures is the largest owner through two funds, with the EIC Fund and Maki.vc also holding significant stakes.

*Percentages are shown before the current equity round.*

Back to top ▲

Use of funds/funding scenarios

The final use of funds depends on how much is raised in this round. The table below shows three scenarios based on different levels of Invesdor participation alongside the anchor investors, who together have committed €500,000. The total round is planned between €1,000,000 and €2,000,000, of which €500,000–€1,500,000 is expected to come through Invesdor.

In all scenarios, the funds will be used to scale the seizure‑monitoring system in Europe, prepare and launch it in the US home market, further improve the AI detection capabilities and integrate the product more deeply into partner hospital and monitoring systems.

Back to top ▲

Actual and planned figures

Get an insight into the company's financial figures, such as turnover and earnings development. Learn more about the growth forecast.

Exit scenarios

Neuro Event Labs is building a business that could be attractive to strategic buyers and financial investors once it has scaled in Europe and the US. The company follows a typical MedTech path where exits often happen through acquisitions by larger industry players or specialist healthcare funds.

Back to top ▲

Risk summary (simplified)

Investments in growth companies always involve risks. You can lose part or all of the money you invest.

The following text is a short and strongly simplified overview of selected risks of an investment in Neuro Event Labs.
It is not complete and does not replace the detailed description of risks in the Key Investment Information Sheet (KIIS).

Before you invest, you must read the KIIS in full and with care and check whether you can understand and bear all of the risks described there.
If there are any differences between this summary and the KIIS, only the KIIS is legally binding.

• Business, market and management risk
  NEL is still at an early growth stage. Revenues from pharma research projects are volatile because contracts are often agreed project‑by‑project, not on a long‑term basis. Growth in the hospital and home monitoring segments also depends heavily on third‑party distribution partners that NEL cannot fully control. At the same time, a relatively small team is handling product development, regulatory work, clinical studies, sales and a new US market launch in parallel, which can lead to delays and execution errors. Even though the Nelli product already generates revenue and has received an FDA Breakthrough Device Designation, there is still a risk that it will not receive full FDA clearance. Overall, this can significantly reduce revenues and company value and, in the worst case, lead to a total loss of your invested capital.
• Sector, regulatory, funding and platform risk
  Demand for NEL’s products and services depends on the general market environment, technological developments and other industries that NEL cannot influence. In addition, NEL operates in a highly regulated health and medtech environment; changes in laws or non‑compliance with regulations may result in sanctions and harm the business. NEL may need additional funding to execute its growth plans and might not be able to raise it at all or only on unfavourable terms. There is also a risk that the crowdfunding platform is temporarily or permanently unavailable or ceases operations. This can cause delays in subscriptions, payment processes or repayments due to revocations, even though your contractual rights in principle remain in place.
• Default, return and liquidity risk
  If NEL cannot implement its growth strategy as planned, fails to win enough contracts or cannot secure further funding, the company may face financial difficulties or insolvency. In such a case, distributions, repayments or a later share sale may be lower than expected, delayed or may not occur at all – up to a complete loss of your invested capital. NEL’s valuation and financial projections are based on assumptions that may prove too optimistic. As a growth‑oriented company, NEL may retain profits instead of paying dividends, so investors may receive no or only limited cash returns. The shares are not listed on a stock exchange, there is no active secondary market and transferability is restricted. You may therefore have to hold your investment for a long time or may only be able to sell at a financial loss.
• Shareholder, dilution, exit and structural risks
  As a minority shareholder, you have only limited influence on key decisions and NEL’s business strategy; majority shareholders can pass resolutions that negatively affect your investment. Future capital increases may dilute your shareholding if you do not, or cannot, participate in later funding rounds. Any return may depend largely on a future sale of the company or an IPO; there is a risk that such an exit does not occur or happens at a lower valuation than expected. Contractual tag‑along and drag‑along provisions may require you to sell your shares at a time or on terms that do not match your preferences. In addition, NEL’s success depends heavily on its management team and qualified employees; the loss of key personnel or difficulties in hiring and retention can weaken business performance.

A complete and detailed description of all risk factors can be found only in the KIIS in the documents section of this funding round

Back to top ▲

There are currently no updates available.

This section will be regularly updated with new, project-relevant information as the financing progresses. To be informed about new updates in a timely manner, subscribe to our newsletter.